Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 3/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20994279 | 0.89 | DPP4 (0.47) | DPP4MC4RS1PR1S1PR5DRD2 | |
| SCHEMBL8685048 | 0.89 | DPP4 (0.47) | DPP4S1PR1S1PR5DRD2DRD3 | |
| SCHEMBL21036764 | 0.89 | DPP4 (0.47) | DPP4MC4RS1PR1S1PR5DRD2 | |
| SCHEMBL1895098 | 0.89 | DPP4 (0.58) | DPP4MC4RMEN1KMT2AS1PR1 | |
| SCHEMBL8685043 | 0.89 | DPP4 (0.47) | DPP4S1PR1S1PR5DRD2DRD3 | |
| SCHEMBL1895282 | 0.87 | DPP4 (0.67) | DPP4MC4RMEN1KMT2AS1PR1 | |
| SCHEMBL8685136 | 0.87 | S1PR1 (0.47) | DPP4MEN1KMT2AS1PR1S1PR5 | |
| SCHEMBL8685134 | 0.87 | S1PR1 (0.47) | DPP4MEN1KMT2AS1PR1S1PR5 | |
| SCHEMBL4011887 | 0.85 | F10 (0.54) | S1PR1S1PR5F10PRSS1RORC | |
| SCHEMBL1920333 | 0.84 | RORC (0.56) | MC4RRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192286-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-09-01 | — | — | US | disclosed |
| WO-2005040109-A1 | LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192286-A1 | Ligands of melanocortin receptors and compositions and methods related thereto | MC3R, MC1R, MC5R | DPP4 3446/4885MC4R 5/4885MEN1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.